Document Detail


Selective serotonin reuptake inhibitor discontinuation syndrome: a review.
MedLine Citation:
PMID:  12008858     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed in the treatment of depression and anxiety, as well as obsessive-compulsive, eating, and impulse-control disorders. Paralleling their widespread use has been an increase in adverse-effect reports not noted during short-term efficacy studies. Significant among these adverse effects is SSRI discontinuation syndrome, which follows the interruption of extended treatment or a reduction in drug dosage and entails somatic and psychological symptoms. These self-limiting symptoms resolve on reintroduction of the drug and cannot be explained as a remanifestation of the original disorder. To facilitate proper diagnosis and avoid unnecessary therapeutic or diagnostic interventions, all physicians who prescribe SSRIs should become familiar with these symptoms. The most appropriate approach to therapy for discontinuation syndrome involves educating patients and reassuring them that this is a reversible condition, reinstating the original SSRI, and further slowing the rate of tapering.
Authors:
Lut Tamam; Nurgul Ozpoyraz
Related Documents :
12073168 - Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-do...
12923828 - Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for d...
10860138 - Citalopram in the treatment of depression.
17264158 - Modafinil therapy for apathy in an elderly patient.
25340958 - Glun2b-containing nmda receptors regulate depression-like behavior and are critical for...
23078158 - Prevalence of gastrointestinal and psychosomatic symptoms among asian patients undergoi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Advances in therapy     Volume:  19     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2002 Jan-Feb
Date Detail:
Created Date:  2002-05-14     Completed Date:  2002-06-06     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  17-26     Citation Subset:  T    
Affiliation:
Cukurova University Faculty of Medicine, Department of Psychiatry, Adana, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antidepressive Agents, Second-Generation / adverse effects*
Humans
Serotonin Uptake Inhibitors / adverse effects*
Substance Withdrawal Syndrome / diagnosis*
Chemical
Reg. No./Substance:
0/Antidepressive Agents, Second-Generation; 0/Serotonin Uptake Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposur...
Next Document:  Efficacy of anakinra in bone: comparison to other biologics.